Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT04586478 is registered in ClinicalTrials.gov with Juventas Cell Therapy Ltd. as lead sponsor.

NCT NCT04586478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04586478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Lead sponsor
Juventas Cell Therapy Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
October 26, 2020
Completion date
September 30, 2025
Enrollment
60 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma